Case Report

Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report

Masashi Oshima, Shozaburou Mayumi, Kai Yazaki, Yuuki Nakamura, Tsuzumi Konishi, Kimitoshi Saito, Satoshi Washino and Tomoaki Miyagawa

Department of Urology, Jichi Medical University Saitama Medical Center, Saitama, Japan

Abbreviations & Acronyms

ALP = alkaline phosphatase
ALT = alanine aminotransferase
AST = aspartate aminotransferase
BUN = blood urea nitrogen
CRPC = castration-resistant prostate cancer
CT = computed tomography
Hb = hemoglobin
LDH = lactate dehydrogenase
Plt = platelet
PSA = prostate-specific antigen
TLS = tumor lysis syndrome
UA = uric acid
WBC = white blood cell

Introduction: Tumor lysis syndrome is a rare and potentially fatal complication of oncological treatment. It is characterized by biochemical changes associated with the rapid lysis of malignant cells, usually after chemotherapy. Tumor lysis syndrome is typically noted in patients with hematological malignancies, and it rarely occurs in patients with solid tumors.

Case presentation: We report a case of tumor lysis syndrome after cabazitaxel administration for metastatic castration-resistant prostate cancer. To our knowledge, tumor lysis syndrome after cabazitaxel therapy has not been reported previously. The patient was a 77-year-old man who developed clinical tumor lysis syndrome after a single dose of cabazitaxel for metastatic castration-resistant prostate cancer. He was treated with hydration and the recombinant uricolytic agent rasburicase, and his condition improved.

Conclusion: It is extremely important to assess the risk factors for tumor lysis syndrome and to perform active prevention procedures in order to avoid fatal outcomes. It may be beneficial to use rasburicase in patients with established tumor lysis syndrome.

Key words: cabazitaxel, castration-resistant prostate cancer, chemotherapy, prostate cancer, tumor lysis syndrome.

Correspondence: Masashi Oshima M.D., Department of Urology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama 330-8503, Japan. Email: m_ohshima@jichi.ac.jp

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Received 29 January 2019; accepted 24 March 2019. Online publication 15 April 2019

Keynote message

We report a case of TLS after cabazitaxel administration for metastatic CRPC. To our knowledge, TLS after cabazitaxel therapy has not been reported previously. It is extremely important to assess the risk factors for TLS and to perform active prevention procedures in order to avoid fatal outcomes. It may be beneficial to use rasburicase in patients with established TLS.

Introduction

TLS is one of the major oncological emergencies. TLS is a potentially lethal complication of anticancer treatment, and it occurs when large numbers of neoplastic cells are killed rapidly, leading to the release of large amounts of intracellular ions and metabolic byproducts into systemic circulation.1,2

It is typically associated with acute leukemia and high-grade non-Hodgkin lymphoma, and TLS in solid tumors, including prostate cancer, have been rarely reported.3

Although occurrences are rare, a literature review revealed 45 case reports of TLS in patients with solid tumors, with a mortality rate of one in three in this patient set.3

Clinically, TLS is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, and these metabolic abnormalities can cause renal dysfunction, arrhythmia, and seizures.5

Here, we report a case of TLS after cabazitaxel administration for metastatic CRPC. To our knowledge, TLS after cabazitaxel therapy has not been reported previously.

© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Case presentation

A 77-year-old man was referred to our department for the treatment of metastatic CRPC. He was diagnosed with metastatic prostate cancer (PSA level >1000 ng/mL, Gleason score 4 + 5, cT4N1M1) at another institution 3 years ago. He received androgen deprivation therapy involving a luteinizing hormone-releasing agonist and nonsteroidal antiandrogen. However, he developed CRPC after 7 months. Thereafter, he received 13 cycles of 3-weekly docetaxel (70 mg/m²) followed by enzalutamide for 8 months at another institution.

Laboratory test results at presentation to our hospital were as follows: PSA, 12.9 ng/mL; serum creatinine, 1.70 mg/dL; potassium, 5.1 mmol/L; corrected calcium, 9.1 mg/dL; phosphorus, 2.7 mg/dL; LDH, 622 U/L; and UA, 6.7 mg/dL.

CT showed a poorly defined prostate tumor, multiple liver metastases, and pelvic lymphadenopathy, and a bone scan showed multiple bone metastases (Fig. 1a–d).

Enzalutamide was changed to cabazitaxel because of multiple liver metastases. Cabazitaxel (20 mg/m²) with dexamethasone (1.0 mg once daily) was initiated. He received pegfilgrastim (6 mg) subcutaneously on day 2 after treatment change as the primary prophylaxis for neutropenia. On day 3, he had fever with a temperature of 37.8°C and severe hypotension (systolic blood pressure, 75 mmHg). At this time, laboratory test results were as follows: serum creatinine, 2.85 mg/dL; potassium, 5.7 mmol/L; phosphorus, 2.8 mg/dL; UA, 11.3 mg/dL; calcium, 6.9 mg/dL; LDH, 2911 U/L; AST, 777 IU/L; ALT, 567 IU/L; and Hb, 6.1 g/dL (Table 1).

Based on the laboratory and clinical findings, he was diagnosed with TLS according to the current classification system of Cairo and Bishop. His hypotension was considered to have been caused by hemorrhagic shock from intratumoral hemorrhage of the liver metastases (Fig. 1e).

He was admitted to the intensive care unit and received hydration therapy (3000 mL/day) and red blood cell transfusion. Correction of hyperuricemia was attempted with a recombinant uricolytic agent (rasburicase, 0.2 mg/kg). After treatment, his UA level decreased to 0 mg/dL at 16 h. Additionally, his electrolyte abnormalities almost resolved after 3 days. He was moved out of the intensive care unit on day 6 and was discharged from the hospital on day 14. However, he was readmitted to our hospital for severe pain and dyspnea 8 days after discharge. At that time, he did not want further examination, then he died of respiratory failure on the next day.

Discussion

TLS is considered a rare and potentially fatal complication of oncological treatment.

Eight cases of TLS have been reported in patients with prostate cancer, and the present case is the ninth TLS case (Table 2). Of the nine cases, five, including our case, occurred after the administration of either chemotherapy or hormonal therapy.

In two cases, patients developed TLS after the initiation of palliative radiation therapy for bone metastasis, whereas in two other cases, patients developed TLS spontaneously without any treatment. All patients had evidence of metastatic disease, and six of the nine cases had CRPC. TLS is defined as the presence of two or more biochemical variables within 3 days before chemotherapy or 7 days after chemotherapy in the condition of adequate hydration and the use of a UA-lowering agent. Certain tumor and patient characteristics can be used to predict the risk of future TLS (e.g. highly proliferating and bulky malignancy, sensitivity to chemotherapy, and exposure to nephrotoxic substances, such as non-steroidal anti-
inflammatory agents and certain antihypertensive medications). Other potential risk factors include presence of decreased renal function and elevated LDH, phosphorus, potassium, and UA levels.3

Additionally, in solid cancer, the presence of liver metastasis is a risk factor for the development of TLS, and this trend was also seen in prostate cancer (Table 2).16

| Table 1 | Patient laboratory values |
|---------|---------------------------|
| | Admission | Day 3 (pre-rasburicase) | Day 4 (post-rasburicase) | Day 5 | Day 9 | Day 12 (before discharge) | Day 22 (readmission) | Normal values |
| WBC | 7460 | 14 140 | 10 100 | 8990 | 7900 | 18 980 | 14 360 | 3900–9800/μL |
| Hb | 9.6 | 6.1 | 6.6 | 7.6 | 8.1 | 9.4 | 9.9 | 12–17.6 g/dL |
| Plt | 31.4 | 14.3 | 7.3 | 8.7 | 20.4 | 28.3 | 32.2 | 13–36.9 x 10^9/μL |
| BUN | 28 | 52 | 38 | 34 | 36 | 33 | 31 | 8–20 mmol/L |
| Creatinine | 1.83 | 2.85 | 1.92 | 1.64 | 1.63 | 1.72 | 1.67 | 0.65–1.07 |
| Potassium | 5.2 | 5.7 | 4.9 | 4.8 | 4.9 | 3.9 | 4.4 | 3.6–4.8 mmol/L |
| Calcium | 8.2 | 6.9 | 6.1 | 6.7 | 8 | 8.4 | 7.4 | 8.4–10.1 mmol/L |
| Phosphorous | 2.4 | 2.8 | 2.2 | 2.4 | 2.2 | 3.2 | 1.7 | 2.7–4.6 mmol/L |
| LDH | 1294 | 2911 | 2184 | 1599 | 1035 | 1502 | 1935 | 124–222 U/L |
| AST | 34 | 777 | 200 | 78 | 33 | 30 | 46 | 13–30 U/L |
| ALT | 34 | 567 | 256 | 146 | 62 | 30 | 70 | 10–42 U/L |
| ALP | 366 | 473 | 338 | 315 | 344 | 376 | 773 | 106–322 U/L |
| UA | 7.6 | 11.3 | 0 | 0.1 | 2.9 | 8.1 | 8.9 | 3.7–7.8 mg/dL |

| Table 2 | Summary of existing case reports of TLS in patients with prostate cancer |
|---------|-------------------------------|
| Author | Year | Patient age | Gleason score | Disease burden | Treatment preceding TLS | Treatment | Outcome | References |
| Tanwetyanon and Choudhury | 2004 | 77 | Not reported | Bone, liver | Fultamide, goserelin | Vigorous supportive measures | Died 8 days following treatment | 7 |
| Sorcher | 2004 | 80 | 3 + 3 | Bone, bone marrow | Docetaxel, dexamethasone | Furosemide | Died 40 h after treatment | 8 |
| Wright et al. | 2005 | 60 | 3 + 4 | Bone, bone marrow | Paclitaxel | Hemodialysis | Died 8 days following treatment | 9 |
| Lin et al. | 2007 | 72 | Not reported | Bone, liver | Fultamide, leuprolide, dexamethasone, medroxy progesterone | Hemodialysis, furosemide, allopurinol | Died 11 days following treatment | 10 |
| Kaplan et al. | 2012 | 60 | 5 + 4 | Bone, bone marrow | Radiation therapy to shoulder | Sodium bicarbonate | Died shortly thereafter | 11 |
| Mazzoni | 2016 | 62 | Not reported | Bone, lymph node, bladder invasion | Palliative radiation therapy, leuprolide, bicartamide | Hemodialysis, rasburicase, sodium bicarbonate | Dialysis dependent, transitioned to hospice | 12 |
| Serling-Boyd et al. | 2017 | 56 | 5 + 4 | Bone, lymph node | None | Allopurinol, sodium bicarbonate, rasburicase | Transferred to hospice | 13 |
| Ignaszewski and Kohlitz | 2017 | 69 | Not reported | Bone, liver | None | Sodium bicarbonate, rasburicase, hemodialysis | Died shortly thereafter | 14 |
| Oshima | 2019 | 77 | 5 + 4 | Bone, liver, lymph node | Cabazitaxel | Sodium bicarbonate, rasburicase, hemodialysis | Died 23 days following treatment | 15 |

In patients having risk factors for TLS, active prevention procedures are of utmost importance to avoid fatal outcomes. Mirrakhimov et al. proposed a risk stratification approach for TLS prevention among patients with solid cancer (Table 2).3

Our patient had abnormal LDH and potassium levels and renal function before cabazitaxel administration; thus, we believe that it might be better to perform TLS prevention procedures.
All patients at risk for TLS should receive hydration to improve renal perfusion and glomerular filtration and to minimize acidosis and oliguria. Hydration is the preferred method of increasing urine output, but diuretics may also be necessary. Reducing the UA level with allopurinol and, particularly, with rasburicase can preserve or improve renal function and reduce serum phosphorus levels as secondary beneficial effects. Although allopurinol prevents the formation of UA, it is less effective than rasburicase for the prevention and treatment of TLS because it prevents xanthine accumulation and directly breaks the UA bond. Rasburicase is considered more effective than allopurinol for the prevention and treatment of TLS because it prevents xanthine accumulation and directly breaks down UA. In our case, after treatment with hydration and rasburicase, the UA level decreased to 0 mg/dL immediately and renal function improved. We believe that it is better to use rasburicase rather than allopurinol for the treatment of established TLS.

In conclusion, we experienced a rare case of TLS after a single dose of cabazitaxel for metastatic CRPC. The use of rasburicase for established TLS is beneficial to decrease the UA level, leading to renal function improvement. However, it is extremely important to assess the risk factors for TLS and to perform active prevention procedures to avoid fatal outcomes.

Conflict of interest
The authors declare no conflict of interest.

References
1. Kelly KM, Lange B. Oncologic emergencies. Pediatr. Clin. North Am. 1997; 44: 809–30.
2. Brinton T, Youssf T, Steinecker G, Rydel J. A case of tumor lysis syndrome in a patient with pancreatic adenocarcinoma treated with low-dose gemcitabine. Ochsner J. 2015; 15: 455–6.
3. Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6: 68–76.
4. Backsgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother. Pharmacol. 2003; 51: 187–92.
5. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ. Tumor lysis syndrome. Semin. Thromb. Hemost. 2007; 33: 397–407.
6. Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004; 127: 3–11.
7. Tanvetyanov T, Choudhury AM. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J. Urol. 2004; 171: 1627.
8. Sorscher SM. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer. Cancer Chemother. Pharmacol. 2004; 54: 191–2.
9. Wright JL, Lin DW, Dewan P, Montgomery RB. Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int. J. Urol. 2005; 12: 1012–3.
10. Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CJ. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. South. Med. J. 2007; 100: 916–7.
11. Kaplan MA, Kucukoner M, Alpagat G, Isikdogana A. Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis. Ann. Saudi Med. 2012; 32: 306–8.
12. Mazzoni S. Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer. Int. Urol. Nephrol. 2016; 48: 1837–8.
13. Serling-Boyd N, Quandt Z, Allaudeen N. Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer. Mol. Clin. Oncol. 2017; 6: 589–92.
14. Ignaszewski M, Kohlitz P. Treatment-naive spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: an unusual suspect. Am. J. Emerg. Med. 2017; 35: 1384.e1–e2.
15. Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin. J. Am. Soc. Nephrol. 2012; 7: 1730–9.
16. Gemici C. Tumour lysis syndrome in solid tumours. Clin. Oncol. (R. Coll. Radiol.) 2006; 18: 773–80.
17. Howard SC. The tumor lysis syndrome. N. Engl. J. Med. 2011; 364: 1844–48.
18. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol. 2001; 19: 697–704.
19. LaRosa C, McMullen L, Bakdash S et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr. Nephrol. 2007; 22: 132–5.